Literature DB >> 32301635

Further understanding of glioma mechanisms of pathogenesis: implications for therapeutic development.

Michael Ruff1,2, Sani Kizilbash2, Jan Buckner2.   

Abstract

Introduction: Recent discoveries in the molecular makeup of gliomas, the relationship of certain molecular drivers, and the patient's response to therapy and overall prognosis have resulted in a paradigm shift and redefined our understanding of glioma and revealed potential vulnerabilities within this recalcitrant and lethal disease.Areas covered: We summarize the current classification of malignant glioma in the context of the historical background, current data-driven treatment strategies, and recent discoveries of the mechanisms of pathogenesis of this disease which recapitulates the developing brain. We describe the relationship to common genetic alterations found in glioma, and possible avenues to exploit these newly revealed mechanisms.Expert opinion: Improved understanding of the molecular underpinnings of this disease has been directly translated into treatment decisions and an improved ability to counsel patients regarding their prognosis. We are beginning to see the first glimmer of a return on the investment in regard to immunotherapy in malignant glioma, with further anticipated successful exploitations of the unique pathophysiology of glioma.

Entities:  

Keywords:  1p/19q; CART; Glioma; IDH; MGMT; NLGN3; TERT; adoptive cell therapy; immunotherapy; tumor heterogeneity

Mesh:

Year:  2020        PMID: 32301635     DOI: 10.1080/14737140.2020.1757440

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  7 in total

1.  TDO2 and tryptophan metabolites promote kynurenine/AhR signals to facilitate glioma progression and immunosuppression.

Authors:  Chuanhong Zhong; Lilei Peng; Bei Tao; Senlin Yin; Liang Lyu; Hao Ding; Xiaobo Yang; Tangming Peng; Haiping He; Peizhi Zhou
Journal:  Am J Cancer Res       Date:  2022-06-15       Impact factor: 5.942

2.  [Atorvastatin inhibits malignant behaviors and induces apoptosis in human glioma cells by up-regulating miR-146a and inhibiting the PI3K/Akt signaling pathway].

Authors:  Y Cui; S Fan; D Pan; Q Chao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-06-20

3.  Deep Convolutional Neural Network-Based Brain Magnetic Resonance Imaging Applied in Glioma Diagnosis and Tumor Region Identification.

Authors:  Zhen Chen; Ning Li; Changtao Liu; Shiwei Yan
Journal:  Contrast Media Mol Imaging       Date:  2022-05-24       Impact factor: 3.009

4.  Influence of GSTP-1 Polymorphism on the Prognosis of Patients with High-Grade Glioma Who Received Temozolomide Plus Radiotherapy Adjuvant Treatment.

Authors:  De-Bao Zhi; Zhi-Yu Wang; Tong Xie; Wen-Wen Tu
Journal:  Int J Gen Med       Date:  2021-12-22

5.  CDC42EP3 promotes glioma progression via regulation of CCND1.

Authors:  Zhigang Yang; Tao Xu; Tao Xie; Liangliang Yang; Guiping Wang; Yang Gao; Gangming Xi; Xiaobiao Zhang
Journal:  Cell Death Dis       Date:  2022-04-01       Impact factor: 8.469

6.  Inflammatory aging clock: A cancer clock to characterize the patients' subtypes and predict the overall survival in glioblastoma.

Authors:  Lei Zhu; Feng Wang; Jiannan Huang; He Wang; Guangxue Wang; Jianxin Jiang; Qinchuan Li
Journal:  Front Genet       Date:  2022-08-11       Impact factor: 4.772

7.  Iron Oxide Nanoparticles Promote Cx43-Overexpression of Mesenchymal Stem Cells for Efficient Suicide Gene Therapy during Glioma Treatment.

Authors:  Ai Li; Tianyuan Zhang; Ting Huang; Ruyi Lin; Jiafu Mu; Yuanqin Su; Hao Sun; Xinchi Jiang; Honghui Wu; Donghang Xu; Hongcui Cao; Xiaoyi Sun; Daishun Ling; Jianqing Gao
Journal:  Theranostics       Date:  2021-07-13       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.